Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-22T16:25:50.185Z Has data issue: false hasContentIssue false
  • English
  • Français

Amelioration of Psychosis with Carbidopa: A Case Report

Published online by Cambridge University Press:  29 January 2018

Markku Linnoila ,
Farouk Karoum ,
Steven G. Potkin ,
Richard Jed Wyatt  and
William Z. Potter
Markku Linnoila*
Affiliation:
Clinical Psychobiology Branch, National Institute of Mental Health, Room 4S-239, Building 10, Bethesda, Maryland 20205 USA
Farouk Karoum
Affiliation:
Adult Psychiatry Branch
Steven G. Potkin
Affiliation:
Adult Psychiatry Branch
Richard Jed Wyatt
Affiliation:
Adult Psychiatry Branch
William Z. Potter
Affiliation:
Clinical Psychopharmacology Unit, Clinical Psychobiology Branch
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Summary

We have recently demonstrated that some patients with atypical bipolar affective disorders, characterized by psychotic manias and depressions, have fluctuating and episodic high urinary phenylethlamine (PEA) excretion. We treated a 30 year old woman, who has this disorder, with 200 mg/24 hours of carbidopa. Her psychosis was ameliorated and the urinary PEA output stabilized to a low normal level. Upon withdrawal of carbidopa her psychosis worsened and improved again when carbidopa treatment was reinstated. Carbidopa did not affect the duration or severity of the patient's mood cycles.

Type
Papers
Information
The British Journal of Psychiatry , Volume 144 , Issue 4 , April 1984 , pp. 428 - 431
Copyright
Copyright © 1984 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bigelow, L. B., Walls, P., Gillin, J. C. & Wyatt, R. J. (1979) Clinical effects of L-5-hydroxtrytophan administration in chronic schizophrenic patients. Biological Psychiatry, 14, 53–68.Google ScholarPubMed
Borison, R. L., Mosnaim, A. D. & Sabelli, H. C. (1974) Biosynthesis of brain 2-phenylethylamine: Influence of decarboxylation and D-amphetamine. Life Sciences, 15, 1836–48.Google Scholar
Bunney, W. J. Jr. & Hamburg, D. A. (1963) Methods for reliable longitudinal observation of behavior. Archives of General Psychiatry, 9, 280–94.Google Scholar
Chuang, L.-W., Karoum, F. & Perlow, M. (1981) A study on the acute effect of amphetamine on the urinary excretion of biogenic amines and metabolites in monkeys. British Journal of Pharmacology, 74, 571–7.Google Scholar
Fisher, E., Heller, D. & Miro, A. H. (1968) β-phenylethylamine in human urine. Arzneimittel Forschung, 18, 1486.Google Scholar
Fisher, E., Spatz, H., Heller, B. & Reggiani, T. L. (1972) Phenylethylamine content of human urine and rat brain. Its alteration in pathological conditions and after drug administration. Experientia, 28, 307–8.Google Scholar
Jeste, D. V., Doongaji, D. R., Danjwani, D., Datta, M., Potkin, S. G., Karoum, F., Thatle, S., Sheth, A. S., Apte, J. S. & Wyatt, R. S. (1981) Cross-cultured study of biochemical abnormality in paranoid schizophrenia. Psychiatry Research, 5, 341–352.CrossRefGoogle Scholar
Karoum, F., Nasrallah, H., Potkin, S., Chuang, L., Moyer-Schwing, J., Phillips, I. & Wyatt, R. J. (1979) Mass fragmentography of phenylethylamine, m- and p-tyramine and related amines in plasma, cerebrospinal fluid, urine and brain. Journal of Neurochemistry, 33, 201–12.Google Scholar
Karoum, F. & Neff, N. H. (1982) Quantitative gas-chromatography-mass spectrometry (GC-MS) of biogenic amines: Theory and practice. In Modern Methods in Pharmacology (ed. Spector, S.) New York: Allen R. Lish pp. 39–54.Google Scholar
Karoum, F., Linnoila, M., Potter, W. Z., Chuang, L.-W., Goodwin, F. K. & Wyatt, R. J. (1982) Fluctuating high urinary phenylethylamine excretion rates in bipolar affective disorder patients. Psychiatry Research, 6, 215–22.Google Scholar
Linnoila, M., Karoum, F. & Potter, W. Z. (1982a) Effect of low dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Archives of General Psychiatry, 39, 513–6.Google Scholar
Linnoila, M., Karoum, F. & Potter, W. Z. (1982b) High correlation of norepinephrine and its major metabolite excretion rates. Archives of General Psychiatry, 39, 521–3.CrossRefGoogle ScholarPubMed
Lorn, V. J. & Porter, C. C. (1970) Potentiation and inhibition of some central actions of L-dopa by decarboxylase inhibitors. Journal of Pharmacology and Experimental Therapeutics, 172, 402–15.Google Scholar
Muscettola, G., Wehr, T. & Goodwin, F. K. (1977) Effect of diet on urinary MHPG excretion in depressed patients and in normal controls. American Journal of Psychiatry, 134, 914–6.Google Scholar
Paulos, M. A. & Tessel, R. E. (1982) Excretion of β-phenethylamine is elevated in profound stress. Science, 215, 1127–9.CrossRefGoogle ScholarPubMed
Philips, S. R. & Boulton, A. A. (1979) The effect of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. Journal of Neurochemistry, 33, 159–67.Google Scholar
Potkin, S. G., Karoum, F., Chuang, L.-W., Cannon-Spoor, H. E., Philips, I. & Wyatt, R. J. (1979) Phenylethylamine in chronic paranoid schizophrenia. Science, 206, 470–1.CrossRefGoogle Scholar
Sandler, M. & Reynolds, G. P. (1976) Does phenylethylamine cause schizophrenia. Lancet i, 70–1.Google Scholar
Spitzer, R. L., Endicott, T. & Robbins, E. (1978) Research Diagnostic Criteria: Rationale and variability. Archives of General Psychiatry, 35, 773–82.Google Scholar
Wyatt, R. J., Gillin, J. C., Stoff, D. M., Mom, E. A. & Tinklenberg, T. R. (1977) β-phenylethylamine (PEA) and the neuropsychiatric disturbances. In Neuroregulators and Psychiatric Disorders, (eds. Usdin, E., Barchas, J., Hamburg, D.) Oxford University Press.Google Scholar
Yang, H.-Y. T. & Neff, N. H. (1974) The monoamine oxidase of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. Journal of Pharmacology and Experimental therapeutics, 189, 733–40.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.